Ayala Pharmaceuticals (NASDAQ:ADXS) Now Covered by StockNews.com

StockNews.com began coverage on shares of Ayala Pharmaceuticals (NASDAQ:ADXS) in a research note issued to investors on Saturday. The brokerage issued a sell rating on the stock.

Ayala Pharmaceuticals Stock Performance

Shares of Ayala Pharmaceuticals stock opened at $0.11 on Friday. Ayala Pharmaceuticals has a 52 week low of $0.00 and a 52 week high of $0.97. The stock has a 50 day moving average price of $0.03 and a two-hundred day moving average price of $0.03. The stock has a market capitalization of $4.48 million, a PE ratio of -0.01 and a beta of 1.63.

About Ayala Pharmaceuticals

Ayala Pharmaceuticals, Inc, a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia.